Attached files
| file | filename |
|---|---|
| EX-31.2 - EXHIBIT 31.2 - ThermoGenesis Holdings, Inc. | ex31-2.htm |
| EX-31.1 - EXHIBIT 31.1 - ThermoGenesis Holdings, Inc. | ex31-1.htm |
| EX-23.1 - EXHIBIT 23.1 - ThermoGenesis Holdings, Inc. | ex23-1.htm |
| EX-10.29 - EXHIBIT 10.29 - ThermoGenesis Holdings, Inc. | ex10-29.htm |
| 10-K - FORM 10-K - ThermoGenesis Holdings, Inc. | kool20170630_10k.htm |
Exhibit 32
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the annual report of Cesca Therapeutics Inc. (the “Company”) on Form 10-K for the period ended June 30, 2017, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers of the Company certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to such officer’s knowledge:
|
(1) |
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|
(2) |
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of the dates and for the periods expressed in the Report. |
|
Dated: September 21, 2017 |
/s/Chris Xu | |
|
|
Chris Xu Chief Executive Officer
| |
|
Dated: September 21, 2017 |
/s/ Jeff Cauble | |
|
Jeff Cauble Principal Financial and Accounting Officer | ||